Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
KOBAYASHI PHARMACEUTICAL CO.,LTD. (4967): Earnings Forecast vs Actual Variance
Source disclosure: February 03, 2026
KOBAYASHI PHARMACEUTICAL CO.,LTD. [4967.T]
TOKYO, Feb 03 (Pulse News Wire) – KOBAYASHI PHARMACEUTICAL CO.,LTD. (4967) reported variances between its previously announced consolidated earnings forecast and actual results. FORECAST REVISION SUMMARY: (Unit: ) Revenue Op Profit Ord Profit Net Profit Forecast (A) 171,000 14,000 15,300 10,500 Actual Results (B) 165,700 14,900 16,900 3,600 Change (B-A) 5,300 900 1,600 6,900 Change (%): Revenue +3.1% | OP
